DiaMedica Therapeutics Inc. (DMAC) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $231.32M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-37.00K; Retained Earnings (Accumulated Deficit)USD $-192.95M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $230.07M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-26.00K; Retained Earnings (Accumulated Deficit)USD $-182.81M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $228.83M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $50.00K; Retained Earnings (Accumulated Deficit)USD $-172.77M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $215.60M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $50.00K; Retained Earnings (Accumulated Deficit)USD $-164.03M.
DiaMedica Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $231.32M | $-37.00K | $-192.95M | $38.34M | (m) | (m) |
| 2026-03-31 | $0.00 | $230.07M | $-26.00K | $-182.81M | $47.23M | (m) | (m) |
| 2025-12-31 | $0.00 | $228.83M | $50.00K | $-172.77M | $56.11M | (m) | (m) |
| 2025-09-30 | $0.00 | $215.60M | $50.00K | $-164.03M | $51.62M | (m) | (m) |
| 2025-06-30 | $0.00 | $182.59M | $-14.00K | $-155.41M | $27.17M | (m) | (m) |
| 2025-03-31 | $0.00 | $181.66M | $5.00K | $-147.71M | $33.95M | (m) | (m) |
| 2024-12-31 | $0.00 | $180.70M | $23.00K | $-140.00M | $40.72M | 12 month · $100.00K | (m) |
| 2024-09-30 | $0.00 | $179.99M | $81.00K | $-132.10M | $47.96M | (m) | (m) |
| 2024-06-30 | $0.00 | $179.29M | $-51.00K | $-125.83M | $53.41M | 3 month · $100.00K | (m) |
| 2024-03-31 | $0.00 | $167.10M | $-39.00K | $-120.71M | $46.35M | (m) | (m) |
| 2023-12-31 | $0.00 | $166.61M | $6.00K | $-115.56M | $51.06M | 12 month · $1.40M | (m) |
| 2023-09-30 | $0.00 | $166.15M | $-127.00K | $-110.40M | $55.63M | 3 month · $4.00K | (m) |
| 2023-06-30 | $0.00 | $165.73M | $-63.00K | $-105.93M | $59.74M | 3 month · $1.40M | (m) |
| 2023-03-31 | $0.00 | $128.50M | $-29.00K | $-101.45M | $27.02M | (m) | (m) |
| 2022-12-31 | $0.00 | $128.08M | $-74.00K | $-96.18M | $31.83M | 12 month · $151.00K | (m) |
| 2022-09-30 | $0.00 | $127.67M | $-162.00K | $-92.43M | $35.08M | (m) | (m) |
| 2022-06-30 | $0.00 | $127.25M | $-167.00K | $-89.37M | $37.72M | (m) | (m) |
| 2022-03-31 | $0.00 | $126.88M | $-107.00K | $-86.01M | $40.77M | (m) | (m) |
| 2021-12-31 | $0.00 | $126.58M | $-51.00K | $-82.50M | $44.02M | 12 month · $151.00K | (m) |
| 2021-09-30 | $0.00 | $126.30M | $-5.00K | $-79.25M | $47.04M | 3 month · $100.00K | 3 month · $303.00K |
| 2021-06-30 | $0.00 | $96.13M | $-3.00K | $-75.81M | $20.32M | (m) | 3 month · $446.00K |
| 2021-03-31 | (m) | $95.68M | $-4.00K | $-72.53M | $23.14M | (m) | 3 month · $511.00K |
| 2020-12-31 | $0.00 | $94.92M | $-2.00K | $-68.91M | $26.01M | (m) | (m) |
| 2020-09-30 | (m) | $94.46M | $10.00K | $-64.71M | $29.76M | 3 month · $1.80M | 3 month · $508.00K |
| 2020-06-30 | (m) | $72.76M | $29.00K | $-61.52M | $11.27M | (m) | 3 month · $436.00K |
| 2020-03-31 | (m) | $72.32M | $42.00K | $-59.04M | $13.32M | (m) | 3 month · $393.00K |
| 2019-12-31 | (m) | $64.23M | $2.00K | $-56.62M | $7.62M | (m) | (m) |
| 2019-09-30 | (m) | $63.83M | $6.00K | $-54.14M | $9.70M | (m) | (m) |
| 2019-06-30 | (m) | $63.38M | $11.00K | $-51.69M | $11.70M | (m) | (m) |
| 2019-03-31 | (m) | $63.12M | $3.00K | $-49.22M | $13.91M | (m) | (m) |
| 2018-12-31 | (m) | $62.99M | (m) | $-45.97M | $17.02M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $4.11M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $5.36M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $6.75M | (m) | (m) |
| 2017-12-31 | (m) | $41.03M | (m) | $-40.23M | $799.00K | 12 month · $292.00K | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $1.11M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |